QGenta

Employing novel heterocyclic chemistry to develop drugs to treat cancers and protein folding disorders

  • Stage Product In Development
  • Industry Biotechnology
  • Location Aurora, CO, USA
  • Currency USD
  • Founded December 2008
  • Employees 4

Company Summary

QGenta is an early stage biopharmaceutical company that undertakes preclinical development of molecular targeted therapeutics to treat cancers and pathologies caused by aberrant protein folding.

Team

  • David Ross
    Professor and Department Chairman

    Professor and Department Chairman Skaggs School of Pharmacy, Department of Pharmaceutical Sciences, University of Colorado

  • Christopher J Moody
    Sir Jesse Boot Professor

    Sir Jesse Boot Professor School of Chemistry University of Nottingham

  • David Siegel
    Research Associate Professor

    Research Associate Professor, Skaggs School of Pharmacy, Department of Pharmaceutical Sciences, University of Colorado

  • Paul Jarosz
    Pharmaceutical Consultant

  • David Siegel

Advisors

  • Kendall Koenig & Oelsner PC Attention Kevin Gibson 999 Eighteenth Street, Suite 1825 North Tower Denver, CO 80202
    Lawyer
    Unconfirmed
    Russell Baker, CPA, MT The Baker Group
    Accountant
    Unconfirmed

Previous Investors

  • University of Nottingham, UK
    Unconfirmed
    State of Colorado (OEDIT)
    Unconfirmed
    University of Colorado Technologies Transfer
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free